Antiplatelet drugs for secondary prevention of stroke
Patients with stroke or TIA should receive two weeks of aspirin followed by definitive anti-platelet treatment (1):
- clopidogrel is recommended as an option to prevent occlusive vascular events:
- for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease or
- for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated
- modified-release dipyridamole in combination with aspirin is recommended as an option to prevent occlusive vascular events:
- for people who have had a transient ischaemic attack or
- for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated
- modified-release dipyridamole alone is recommended as an option to prevent occlusive vascular events:
- for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated or
- for people who have had a transient ischaemic attack only if aspirin is contraindicated or not tolerated
People currently receiving clopidogrel or modified-release dipyridamole either with or without aspirin outside the criteria detailed above should have the option to continue treatment until they and their clinicians consider it appropriate to stop
Reference:
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.